

ASX ANNOUNCEMENT

31 January 2025

Release of Securities from Mandatory Escrow

Vitrafy Life Sciences Limited (ASX: VFY), (**Vitrafy** or **Company**) advises in accordance with ASX Listing Rule 3.10A, the following restricted securities will be released from mandatory escrow as follows:

ASX Code	Securities	Escrow Release Date
VFYAA	271,740 Fully Paid Ordinary Shares	8 February 2025
VFYAB	9,058 Fully Paid Ordinary Shares	21 February 2025

The Company will apply for the quotation of these securities within 5 business days after the end of the escrow period in accordance with ASX Listing Rule 2.8.5.

As outlined in Vitrafy's Pre-Quotation Disclosure Statement dated 22 November 2024, the above securities will continue to be subject to voluntary escrow arrangements with the voluntary escrow period to end in respect of:

- 25% of the securities, after release of the audited accounts for the Company for the financial year ended 30 June 2025; and
- 75% of the securities, after release of the audited accounts for the Company the financial year ended 30 June 2026.

ENDS

This announcement is authorised by the Board of Vitrafy Life Sciences Limited.

For further information contact:

Investor and Media Relations Simon Martin Chief Financial Officer investors@vitrafy.com

About Vitrify

Vitrafy has developed a proprietary range of smart cryopreservation hardware and Lifechain[™], a cloud-based software platform, to offer a complete cryopreservation solution. This integrated system ensures the preservation of biomaterial quality, empowering industries to retain the integrity of sensitive biological samples throughout the storage process. Vitrafy's innovative approach combines cutting-edge technology and seamless software integration to optimise cryopreservation, ensuring reliability and efficiency in maintaining valuable biological assets. Vitrafy is headquartered in Melbourne, Australia and is listed on the Australian Securities Exchange (ASX: VFY).

For more information visit vitrafy.com.